COMMUNIQUÉS West-GlobeNewswire
-
Erasca to Present at the 8th Annual Evercore Healthcare Conference
25/11/2025 -
Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer
25/11/2025 -
Lancement du Prix AbbVie des innovateurs en biotechnologies au Québec : AbbVie et adMare BioInnovations encouragent l’innovation dans le domaine des sciences de la vie
25/11/2025 -
AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
25/11/2025 -
San Diego’s Premier Neurological-Spine Care Clinic Launches Massive Holiday NUCCA Promotion: 50% Off for New Patients Through Dec. 31
25/11/2025 -
LifeLabs Donates $10,000 to Women in Crisis in Honour of the International Day for the Elimination of Violence Against Women and Girls.
25/11/2025 -
Branded Legacy Announces Strong Revenues from Newly Acquired Pau Hana Subsidiary
25/11/2025 -
Health Care Resource Centers Appoints Dr. Katherine Krauskopf as Regional Medical Director in Western Massachusetts
25/11/2025 -
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
25/11/2025 -
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
25/11/2025 -
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
25/11/2025 -
Kraig Biocraft Laboratories Launches Significant Hiring Initiative to Support Expanded Spider Silk Production Footprint in Southeast Asia
25/11/2025 -
Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial
25/11/2025 -
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
25/11/2025 -
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
25/11/2025 -
BridgeBio to Participate in December Investor Conferences
25/11/2025 -
BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025
25/11/2025 -
BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company’s Growth Strategy and Deep TMS™ Treatment December 1, 2025
25/11/2025 -
Flare Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
25/11/2025
Pages